US Advises Seniors Against Getting Chikungunya Vaccine Due to Safety Concerns
US health officials advise travelers aged 60 and above to avoid the chikungunya vaccine amid ongoing safety investigations due to potential side effects in older adults.
In recent health developments, US health authorities have issued a cautionary message to travelers aged 60 and above, recommending against receiving the chikungunya vaccine while investigations into potential side effects are ongoing. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) released notices last week concerning the vaccine, Valneva's Ixchiq, which was previously recommended for adults traveling to regions affected by chikungunya.
Chikungunya is a mosquito-borne illness endemic to tropical areas, characterized by high fever, severe joint pain, and fatigue. Despite its typically mild initial symptoms, the disease can cause prolonged joint issues and significant health problems. Annually, around 100 to 200 cases are reported in the United States among travelers returning from affected regions.
The vaccine, developed using a weakened form of the chikungunya virus, was introduced last year as a preventive measure for at-risk populations. However, recent reports have raised safety concerns, particularly regarding older adults. A review by vaccine experts revealed six cases of individuals aged 65 and above who experienced heart or brain-related symptoms shortly after vaccination. Notably, most of these individuals had preexisting health conditions. Additional similar cases have been documented internationally.
Regulatory agencies in Europe are also examining these cases as part of their review process. In response to the emerging data, US advisory panels have recommended placing a precaution on the vaccine’s use in seniors over 65. Meanwhile, another chikungunya vaccine by Bavarian Nordic, Vimkunya, remains recommended for travelers aged 12 and older, though decisions on its widespread use are yet to be finalized.
This development underscores the importance of carefully evaluating vaccine safety, especially in vulnerable populations. Travelers are advised to consult healthcare providers for personalized recommendations and remain informed about ongoing safety assessments regarding chikungunya vaccination.
Source: https://medicalxpress.com/news/2025-05-health-older-chikungunya-vaccine.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Aging Reduces Overactive Immune Genes, Leading to Improvement in Lupus Symptoms in Older Adults
Aging appears to diminish the activity of immune-related genes in lupus patients, potentially leading to symptom improvement in older adults. This discovery opens new possibilities for age-specific treatments and understanding disease progression.
Discovery of a Key Gene That Influences Liver's Energy Storage Strategy
A groundbreaking study uncovers how the PPP1R3B gene acts as a metabolic switch in the liver, influencing whether energy is stored as sugar or fat—a discovery with potential implications for managing metabolic diseases like diabetes and fatty liver.
Are 'Kissing Bugs' Spreading Disease in Virginia? A Closer Look at Chagas' Disease Risk
Recent evidence suggests that kissing bugs, carriers of Chagas' disease, are spreading further north in the U.S., including Virginia, raising awareness about this potentially serious parasitic infection.
Groundbreaking Research Identifies Early Brain Target to Prevent Alzheimer's Disease
New research identifies TSPO protein as an early biomarker of Alzheimer's, opening pathways for early detection and intervention to delay disease progression.